That's generally exactly what we do, which if we need to follow 2x or 10x incidental lesions in the population, leads to cost and availability problems. A lymphoma patient in remission needs follow up scans too, and I don't want them to have to wait 3 months because thousands of people are now following up their benign adrenal adenomas.